<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-19_08-31-33</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Platinum‑resistant recurrent ovarian clear cell carcinoma with multifocal progression and severe anemia; current visit must focus on stabilization, goals of care, and deferring new oncologic interventions until status clarified.

Core Treatment Strategy:
- Immediately assess ECOG, detailed symptoms, and explicit goals/preferences during this visit before any new cancer therapy decisions.  
- Urgently work up and correct severe anemia with full CBC/indices, iron studies, CMP, and coagulation profile [@20230103|2023-01-03].  
- Defer new CT/MR/PET‑CT and extended biomarkers (MSI, PD‑L1, TMB, HER2) unless clearly management‑changing [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  
- After stabilization, revisit with patient whether to pursue non‑platinum palliative systemic therapy versus best supportive care alone in this relapse setting [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  

Change Triggers:
- If anemia corrected and ECOG ≤2 with patient desiring active treatment, shift toward selecting a non‑platinum palliative systemic regimen.  
- If ECOG poor, symptoms high, or patient prefers comfort‑focused care, pivot fully to best supportive and hospice‑oriented management.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）术后白紫+卡铂化疗6程，末次：2022.8.172022.08.15：CA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/ml↑,CEA:1.92ng/ml,HE4:87.90pmol/L↑,ROMA:23.55%(绝经前)↑,ROMA.:18.89%(绝经后)MR（2022.07.17）：2022.08.15：CA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/ml↑,CEA:1.92ng/ml,HE4:87.90pmol/L↑,ROMA:23.55%(绝经前)↑,ROMA.:18.89%(绝经后)肿瘤标志物（2022.10.12）：CA19-9:77.20U/ml↑,CA125:89.60U/ml↑,AFP:&lt;0.91ng/ml,CEA:1.31ng/ml,HE4:59.70pmol/L,ROMA:12.07%(绝经前)↑,ROMA.:36.67%(绝经后)↑。CT（2022.10.25）：肝内多发结节，部分较前新见，转移可能，请结合MR检查。另见肝囊肿同前。MR（2022.10.24）：盆腔术后，骶前占位，考虑复发伴相邻骶骨受累可能。盆腔系膜多发强化小结节，转移可能。2022.11.10外院血常规：白细胞 2.36，红细胞 3.56，血红蛋白 97，血小板 153外院生化：ALP　105，NA 136，PAB 1242022.11.30外院血常规：白细胞 3.46，红细胞 3.48，血红蛋白 94，血小板 1342022.11.17外院肿瘤指标：CA125　403，Ca153　63.8，Ca199 96.8，Ca724 695肿瘤标志物（2022.12.29）：CA19-9:229.00U/ml↑,CA125:933.00U/ml↑,CA15-3:86.00U/ml↑,CEA:1.49ng/ml,NSE:9.06ng/ml,HE4:111.00pmol/L↑,ROMA:41.02%(绝经前)↑,ROMA.:85.98%(绝经后)↑。MR（2022.12.30）：盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。右侧髂骨新见强化结节，转移可能。盆腔系膜多发强化小结节同前相仿，转移可能。直肠局部肠壁增厚伴强化。CT（2022.12.30）：肝内多发转移结节，较前增多，部分较前增大。另见肝囊肿同前。脾脏片状影，脾脏梗塞？随访。咨询报告</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6 cycles&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;白紫+卡铂&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;&lt;0.91 ng/ml (2022-10-12)&quot;,&quot;CA125&quot;:&quot;933.00 U/ml (2022-12-29)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Recurrent ovarian carcinoma with hepatic and pelvic metastatic disease&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;高级别腺癌&quot;],&quot;histology&quot;:&quot;首先考虑为透明细胞癌&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;卵巢癌复发&quot;,&quot;site&quot;:&quot;卵巢&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;intent&quot;:&quot;Adjuvant&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;白紫+卡铂&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;56&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;56&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;evidence&quot;:&quot;CA125:89.60U/ml (2022-10-12)&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;Unknown&quot;,&quot;status&quot;:&quot;Resistant&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;56&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Resistant&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Resistant&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;evidence&quot;:&quot;CA125:89.60U/ml&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;SCENE&quot;:&quot;Platinum_resistant_relapse&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Debulking surgery + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last administration recorded 2022-08-17&quot;,&quot;regimen_or_test&quot;:&quot;白紫+卡铂&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Tumor markers rising after chemotherapy&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:&lt;0.91ng/ml&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, AFP&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT: multiple hepatic nodules, some new, likely metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Tumor markers markedly elevated&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, CA15-3&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis, CT abdomen&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-03&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-08-17&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;45.7&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;14.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;89.60&quot;},{&quot;date&quot;:&quot;2022-11-17&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;403&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;933.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;933.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;161&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.16&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;77.20&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;229.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;229.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;562&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;87.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;59.70&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;111.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;111.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;},{&quot;analyte&quot;:&quot;Hb&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-11-10&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;97&quot;},{&quot;date&quot;:&quot;2022-11-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;94&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-11-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;94&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;g/L&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Primary debulking surgery&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of 白紫+卡铂&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical relapse with rising CA125&quot;,&quot;type&quot;:&quot;Relapse&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Unknown&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;白紫+卡铂 (6 cycles)&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;高级别腺癌&quot;],&quot;date&quot;:&quot;2022-03-28&quot;,&quot;diagnosis&quot;:&quot;部分直乙结肠+左侧腹膜后肿瘤+部分阴道: 肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌；可符合卵巢透明细胞癌累及。&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;MLH1&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;(部分+)&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;(少弱+)&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;(+/-)&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;(60%+)&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;(灶+)&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;SALL4&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;ZBTB16&quot;,&quot;result&quot;:&quot;(-)&quot;}],&quot;involvement_sites&quot;:[&quot;intestinal wall full thickness&quot;,&quot;peritoneum (left retroperitoneal tumor)&quot;,&quot;vagina (partial)&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;partial rectosigmoid + left retroperitoneal tumor + partial vagina&quot;,&quot;tumor_size&quot;:&quot;7*4*2.5cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;Molecular/genetic testing not reported&quot;,&quot;Definitive origin laterality not specified&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;pelvis&quot;,&quot;sacrum&quot;],&quot;date&quot;:&quot;2022-10-24&quot;,&quot;findings&quot;:[&quot;Pelvis post-op changes&quot;,&quot;presacral mass, consider recurrence with adjacent sacral involvement&quot;,&quot;multiple enhancing small mesenteric nodules in pelvis, suggest metastases&quot;],&quot;impression&quot;:&quot;Recurrence with possible sacral involvement and pelvic mesenteric metastases&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;liver&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Multiple hepatic nodules, some new compared to prior&quot;,&quot;hepatic cysts unchanged&quot;],&quot;impression&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;pelvis&quot;,&quot;right iliac bone&quot;,&quot;sacrum&quot;,&quot;rectum&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Presacral mass increased in range with heterogeneous enhancement&quot;,&quot;new enhancing nodule in right iliac bone&quot;,&quot;multiple pelvic mesenteric enhancing nodules&quot;,&quot;rectal local bowel wall thickening with enhancement&quot;],&quot;impression&quot;:&quot;Progressive pelvic recurrence with possible peritoneal and sacral involvement; new right iliac bone lesion&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;liver&quot;,&quot;spleen&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Multiple hepatic metastatic nodules increased in number and size&quot;,&quot;patchy splenic shadow, possible splenic infarct&quot;],&quot;impression&quot;:&quot;Progressive hepatic metastases; splenic abnormality noted, follow-up suggested&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last administration recorded 2022-08-17&quot;,&quot;regimen_or_test&quot;:&quot;白紫+卡铂&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Tumor markers rising after chemotherapy&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:&lt;0.91ng/ml&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, AFP&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT: multiple hepatic nodules, some new, likely metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Tumor markers markedly elevated&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, CA15-3&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis, CT abdomen&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: 350
- name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究
- Reason: 复发转移性卵巢透明细胞癌、标准治疗失败且为妇科恶性肿瘤，符合该晚期实体瘤篮式试验的疾病类型与治疗线要求。
- Missing eligibility confirmations (0-2 items):
  - 是否符合该试验对全身状况及器官功能的具体要求
  - 是否存在任何未披露的试验排除性合并症或既往用药史</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Profound anemia (HGB 74 g/L) and unknown ECOG/organ function make immediate intensive systemic therapy decisions unsafe; prioritize urgent correction/workup of anemia and full status assessment before committing to next‑line regimen.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Given progressive multifocal disease and possible splenic infarct, clarify whether any further cross‑sectional imaging (including PET‑CT) would realistically change RT/local or systemic planning before ordering.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>From a systemic perspective I need ECOG, symptom burden, current full labs, and updated cross‑sectional imaging before judging suitability for further non‑platinum therapy versus best supportive care; without these, treatment risk–benefit is impossible to assess.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>Last CT/MR (2022-12-29/30) show clear progression and possible splenic infarct; updated cross‑sectional imaging is critical before further RT/systemic decisions.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>MMR is intact but MSI, PD-L1, TMB, and HER2 remain untested; if further systemic therapy hinges on immunotherapy/targeted options, these biomarkers need clarification or explicit decision to forego testing. [@case_view|2022-03-28]</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>No PET-CT is documented; please clarify if PET-CT is planned, as it may refine RT/surgical fields or prove redundant in this palliative context.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>Given progressive pelvic, hepatic, and possible splenic involvement, please confirm whether any more recent cross-sectional imaging or PET-CT is available to avoid duplicating studies.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>We now have conflicting views on imaging urgency versus systemic-planning readiness; please explicitly prioritize immediate correction/workup of severe anemia and ECOG/symptom assessment before committing to additional imaging or next-line systemic therapy.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Given clear radiologic progression, profound anemia (HGB 74 g/L), and unknown ECOG/symptoms, I cannot safely recommend further systemic therapy until performance status, anemia workup/optimization, and goals of care are clarified; best supportive care alone must be explicitly considered.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>radiologist</td><td class='mono'>nuclear</td><td>No imaging newer than the 2022-12-29/30 CT/MR is available in the record; any already-scheduled PET-CT should be checked to prevent duplicate staging.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Advanced, rapidly progressive platinum‑resistant clear cell ovarian carcinoma with liver, pelvic, bone metastases; intent now palliative disease control and symptom relief.  \n\n- Before firm systemic and local therapy planning, update ECOG/organ function (full CMP, coagulation), pain status, GI/urinary function, and patient preferences.  \n\n- Given platinum‑resistant relapse and clear cell histology, prioritize non‑platinum systemic options, trial consideration, and supportive care integration [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].&quot;,
  &quot;oncologist&quot;: &quot;- Early biochemical and radiologic relapse (&lt;6 months) after adjuvant platinum suggests platinum-resistant clear cell ovarian carcinoma; favor non‑platinum relapse strategy. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]\n\n- HRD- and BRCA-wildtype status plus clear cell histology reduces expected benefit from PARP-based maintenance or relapse strategies. [@OH2203828|2022-04-18]\n\n- Before regimen choice, need updated performance status, symptoms, full renal/hepatic profile, anemia workup/management plan, and detailed imaging for resectability.&quot;,
  &quot;radiologist&quot;: &quot;- Interval progression of presacral pelvic recurrence with suspected sacral and right iliac bone involvement; multiple stable pelvic mesenteric nodules. [@2022-12-29|MR]  \n\n- Hepatic metastatic disease has increased in number and size; splenic low-density area suspicious for infarct, needs imaging follow-up. [@2022-12-29|CT]  \n\n- Overall imaging shows worsening multifocal metastatic disease (pelvis, liver, bone), consistent with progressive recurrent gynecologic malignancy. [@2022-12-29|MR] [@2022-12-29|CT] [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]&quot;,
  &quot;pathologist&quot;: &quot;- Histology and IHC support diagnosis of ovarian clear cell carcinoma involving rectosigmoid wall, retroperitoneum, and vagina. [@case_view|2022-03-28]\n\n- MMR proteins intact; MSI, PD-L1, TMB, and HER2 status remain unknown/needs update. [@case_view|2022-03-28]\n\n- Germline ATM p.Y316C detected; HRD negative; no pathogenic BRCA1/2 or ARID1A/PTEN/PIK3CA alterations identified. [@OH2203828|2022-04-18]&quot;,
  &quot;nuclear&quot;: &quot;- No PET-CT available; PET status of pelvic, hepatic, splenic, and bone lesions is unknown/needs update before metabolic staging.  \n\n- Cross-sectional imaging shows progressive pelvic recurrence with sacral, peritoneal, right iliac bone involvement and hepatic metastases, implying advanced metastatic stage [@2022-12-29|MR][@2022-12-29|CT].  \n\n- In recurrent ovarian cancer, PET-CT can upstage disease by detecting additional nodal/peritoneal metastases, influencing surgical/RT planning [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- First, urgently assess ECOG, symptoms, and anemia etiology/need for transfusion or iron therapy before any further oncologic intervention [@20230103|2023-01-03].  \n\n- In parallel, repeat full labs (CBC with indices, CMP, coagulation) and clarify goals of care, explicitly including best supportive care option.  \n\n- Once status optimized, consider non‑platinum palliative systemic strategy versus best supportive care, and order PET‑CT/biomarkers only if management‑changing [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].&quot;,
    &quot;oncologist&quot;: &quot;- Urgently evaluate and treat severe anemia (HGB 74 g/L) and obtain ECOG, symptom profile, goals of care before systemic decisions. [@20230103|2023-01-03]\n\n- After stabilization and status review, reassess candidacy for non‑platinum palliative systemic therapy versus best supportive care only. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]\n\n- Defer new imaging, PET‑CT, and extended biomarkers (MSI, PD‑L1, TMB, HER2) until above assessment clarifies that results would alter management.&quot;,
    &quot;radiologist&quot;: &quot;- Defer new imaging (CT/MR/PET‑CT) until ECOG, symptom burden, and anemia workup/optimization are clarified and goals of care defined. [@2022-12-29|CT] [@2022-12-29|MR] [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \n\n- If patient deemed candidate for further RT/local intervention, then obtain updated contrast CT/MR to reassess pelvic, hepatic, and splenic status. [@2022-12-29|CT] [@2022-12-29|MR]  \n\n- PET‑CT to be considered only if its results would clearly alter RT fields or local procedures; currently not mandatory. Unknown if scheduled.&quot;,
    &quot;pathologist&quot;: &quot;- Urgently assess ECOG, symptom burden, and fully evaluate/correct profound anemia (HGB 74 g/L) before any new therapy decisions. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15; @report_unknown|2022-12-29]\n\n- Defer new systemic therapy choices until anemia workup, organ function labs, and patient goals/preferences are clarified. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10]\n\n- Reconsider need and timing of further imaging (CT/PET-CT) only after clinical stabilization and if results would alter RT/local/systemic strategy. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]&quot;,
    &quot;nuclear&quot;: &quot;- Verify whether a PET-CT has already been scheduled; avoid duplicate staging given recent progressive CT/MR findings [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Defer new PET-CT ordering until ECOG, anemia workup, and goals-of-care review clarify whether PET would change RT/local planning [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  \n\n- If curative-intent RT or focused palliation (e.g., sacrum/right iliac bone) becomes realistic, reconsider targeted PET-CT for precise field delineation.&quot;
  },
  &quot;Round 2&quot;: {
    &quot;chair&quot;: &quot;- Immediately clarify ECOG, symptom burden, goals of care, and fully evaluate/treat severe anemia with full labs including iron studies [@20230103|2023-01-03].  \n\n- After stabilization, jointly decide between non‑platinum palliative systemic therapy versus best supportive care alone, based on performance status and wishes [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n\n- Defer new CT/MR/PET‑CT and extended biomarkers (MSI, PD‑L1, TMB, HER2) unless results are clearly expected to change management (e.g., RT planning).&quot;,
    &quot;oncologist&quot;: &quot;- Urgently investigate and correct severe anemia and assess ECOG, symptoms, and goals of care before systemic decisions. [@20230103|2023-01-03]\n\n- After stabilization, reassess candidacy for non‑platinum palliative systemic therapy versus best supportive care alone in this platinum‑resistant relapse. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]\n\n- Defer new CT/MR/PET‑CT and extended biomarkers (MSI, PD‑L1, TMB, HER2) until clearly likely to change management; avoid duplicate PET‑CT.&quot;,
    &quot;radiologist&quot;: &quot;- With recent CT/MR already confirming progressive multifocal disease and suspected splenic infarct, defer new imaging until anemia/ECOG clarified. [@2022-12-29|CT] [@2022-12-29|MR] [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \n\n- If, after stabilization, RT/local intervention is reconsidered for symptom control, then obtain updated contrast-enhanced CT/MR for pelvic, hepatic, splenic reassessment. [@2022-12-29|CT] [@2022-12-29|MR]  \n\n- Reserve PET‑CT for scenarios where findings would concretely alter RT fields or procedures; current PET‑CT scheduling status unknown.&quot;,
    &quot;pathologist&quot;: &quot;- Prioritize urgent workup and correction of severe anemia and full assessment of ECOG, symptoms, and organ function before oncologic decisions. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15; @report_unknown|2022-12-29]\n\n- After stabilization, reassess with patient the balance between non‑platinum palliative systemic therapy and best supportive care alone. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10]\n\n- Defer additional CT/MR/PET‑CT and extended biomarkers (MSI, PD‑L1, TMB, HER2) until clearly expected to change management; avoid duplication. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]&quot;,
    &quot;nuclear&quot;: &quot;- Defer new PET-CT until ECOG, anemia workup, and goals-of-care clarify whether added staging would change management; avoid duplication [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  \n\n- If future RT to sacrum/right iliac bone is considered, a targeted PET-CT could refine metabolically active target volumes [@2022-12-29|MR].  \n\n- For now, rely on recent CT/MR for distribution of pelvic, hepatic, and possible splenic disease; PET contribution remains uncertain [@2022-12-29|CT][@2022-12-29|MR].&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-03</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-03</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;天冬氨酸氨基转移酶 43.0 U/L (AST)\n游离脂肪酸 0.09 mmol/L (NEFA)\n谷氨酸脱氢酶 4.1 U/L (GLDH)\n白蛋白 36.7 g/l (ALB)\n总蛋白 67.0 g/l (TP)\n谷草同工酶 12.7 U/L (ASTM)\n球蛋白 30.3 g/l (GELO)\n直接胆红素 3.2 umol/l (DBIL)\n尿酸 146 umol/l (UA)\n总胆红素 5.1 umol/l (TBIL)\n前白蛋白 98 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n碱性磷酸酶 100.0 U/L (ALP)\n丙氨酸氨基转移酶 40.8 U/l (ALT)\n肌酐 49 umol/l (CRE)\n白球比例 1.21 nan (A/G)\n乳酸脱氢酶 254 U/L (LDH)\n尿素 4.67 mmol/l (UREA)\nγ-谷氨酰基转移酶 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;神经元特异烯醇化酶 9.06 ng/ml (NSE)\n卵巢恶性肿瘤风险值. 85.98 %(绝经后) (ROMA.)\n糖链抗原15-3 86.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 41.02 %(绝经前) (ROMA)\n人附睾蛋白4 111.00 pmol/L (HE4)\n癌胚抗原 1.49 ng/ml (CEA)\n糖链抗原125 933.00 U/ml (CA125)\n糖链抗原19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;中性粒细胞% 76.5 % (GRAN)\nPLT分布宽度 12 % (PDW)\n嗜碱性细胞数 0.01 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n淋巴细胞数 0.5 *10^9/L (LYM#)\n中性粒细胞数 4.8 *10^9/L (GRAN#)\n红细胞计数 2.84 *10^12/L (RBC)\n血小板计数 259 *10^9/L (PLT)\nRBC分布宽度-CV 18.6 % (RDWCV)\n平均红细胞血红蛋白浓度 305.0 g/l (MCHC)\n血小板压积 0.28 % (PCT)\nRBC分布宽度-SD 57 nan (RDWSD)\n单核细胞数 0.9 *10^9/L (MID#)\n自动审核标志 UNACCEPT nan (VFLAG)\n平均红细胞体积 85.6 fl (MCV)\n白细胞计数 6.2 *10^9/L (WBC)\n血红蛋白量 74 g/l (HGB)\n嗜酸性细胞数 0.00 *10^9/L (EOS#)\n嗜酸性细胞% 0.00 % (EOS)\n淋巴细胞% 8.5 % (LYM)\n单核细胞% 14.8 % (MID)\n平均红细胞血红蛋白量 26.1 pg (MCH)\n红细胞比积 24.3 % (HCT)\n平均PLT容积 10.9 fl (MPV)\n中性淋巴比值 9.60 nan (NL)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;天冬氨酸氨基转移酶 43.0 U/L (AST)\n游离脂肪酸 0.09 mmol/L (NEFA)\n谷氨酸脱氢酶 4.1 U/L (GLDH)\n白蛋白 36.7 g/l (ALB)\n总蛋白 67.0 g/l (TP)\n谷草同工酶 12.7 U/L (ASTM)\n球蛋白 30.3 g/l (GELO)\n直接胆红素 3.2 umol/l (DBIL)\n尿酸 146 umol/l (UA)\n总胆红素 5.1 umol/l (TBIL)\n前白蛋白 98 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n碱性磷酸酶 100.0 U/L (ALP)\n丙氨酸氨基转移酶 40.8 U/l (ALT)\n肌酐 49 umol/l (CRE)\n白球比例 1.21 nan (A/G)\n乳酸脱氢酶 254 U/L (LDH)\n尿素 4.67 mmol/l (UREA)\nγ-谷氨酰基转移酶 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;神经元特异烯醇化酶 9.06 ng/ml (NSE)\n卵巢恶性肿瘤风险值. 85.98 %(绝经后) (ROMA.)\n糖链抗原15-3 86.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 41.02 %(绝经前) (ROMA)\n人附睾蛋白4 111.00 pmol/L (HE4)\n癌胚抗原 1.49 ng/ml (CEA)\n糖链抗原125 933.00 U/ml (CA125)\n糖链抗原19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;中性粒细胞% 76.5 % (GRAN)\nPLT分布宽度 12 % (PDW)\n嗜碱性细胞数 0.01 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n淋巴细胞数 0.5 *10^9/L (LYM#)\n中性粒细胞数 4.8 *10^9/L (GRAN#)\n红细胞计数 2.84 *10^12/L (RBC)\n血小板计数 259 *10^9/L (PLT)\nRBC分布宽度-CV 18.6 % (RDWCV)\n平均红细胞血红蛋白浓度 305.0 g/l (MCHC)\n血小板压积 0.28 % (PCT)\nRBC分布宽度-SD 57 nan (RDWSD)\n单核细胞数 0.9 *10^9/L (MID#)\n自动审核标志 UNACCEPT nan (VFLAG)\n平均红细胞体积 85.6 fl (MCV)\n白细胞计数 6.2 *10^9/L (WBC)\n血红蛋白量 74 g/l (HGB)\n嗜酸性细胞数 0.00 *10^9/L (EOS#)\n嗜酸性细胞% 0.00 % (EOS)\n淋巴细胞% 8.5 % (LYM)\n单核细胞% 14.8 % (MID)\n平均红细胞血红蛋白量 26.1 pg (MCH)\n红细胞比积 24.3 % (HCT)\n平均PLT容积 10.9 fl (MPV)\n中性淋巴比值 9.60 nan (NL)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-4-6：肝内多发低密度结节，边界不清，大者约16mm*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常，左输尿管内见支架管影。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发结节，部分较前新见，转移可能，请结合MR检查。 另见肝囊肿同前。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-4-6：肝内多发低密度结节，边界不清，大者约16mm*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常，左输尿管内见支架管影。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发结节，部分较前新见，转移可能，请结合MR检查。 另见肝囊肿同前。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-4-6：肝内多发低密度结节，边界不清，大者约16mm*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常，左输尿管内见支架管影。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发结节，部分较前新见，转移可能，请结合MR检查。 另见肝囊肿同前。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>Recurrent platinum-resistant ovarian clear cell carcinoma post debulking and paclitaxel/carboplatin, with liver, pelvic/peritoneal, sacral and right iliac bone metastases; MMR-proficient; ER/PR low positive; performance/organ function constraints not documented; histology: clear cell carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6530 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10]
    with ﬁrst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected …
[2] score=0.6419 nccn_ovariancancer_v3_2025__v00000000 [PAGE 14] [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]
    ff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of disease; clinical judgment and flexibility should be utilized in determining treatment options. gg Data are limited on primary and maintenance therapy for recurrent/ persistent LCOC. hh During and after treat…
[3] score=0.6259 esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 [PAGE 17] [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000|17]
    17 Table 1 Indications for in vivo ovarian tissue preservation in ovarian neoplasms according to the histological type and the stage of the disease STAGE EPITHELIAL OVARIAN NEOPLASMS NON-EPITHELIAL OVARIAN NEOPLASMS BOT1 LGSC LGEC MCexp CCC HGSC HGEC MCinf GCT2 SCC GrCT SLCT3 SLCT4 IA IB IC1 IC2 ## …
[4] score=0.6247 esmo_cpg_nonepithelialovarian_2018__v00000000 [PAGE 13] [@guideline:esmo_cpg_nonepithelialovarian_2018__v00000000|13]
    nately, none of them has been compared with BEP in randomised trials. A phase II Gynecologic Oncology Group (GOG) trial reported high activity with an acceptable toxicity proﬁle for a carboplatin–etoposide combination in the adjuvant setting of completely resected stages I–III dysgerminomas [40]. Dy…
[5] score=0.6238 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCC…

# PUBMED RAG
PUBMED Evidence Pack (top=5):
[1] score=0.7284 PMID 36591227 [@pubmed:36591227]
    Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma.
    Advanced endometrial clear cell carcinoma (CCC) tends to have poor prognosis owing to aggressive clinical behavior and poor response to conventional chemotherapy. Herein, we report a case of platinum-refractory recurrent ECCC successfully treated with the combination of pembrolizumab, localized radi…
[2] score=0.7256 PMID 35401005 [@pubmed:35401005]
    Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.
    Ovarian clear cell carcinoma (OCCC) is a highly aggressive malignancy with a poor prognosis, and most patients experience recurrence after primary treatment. Currently, there is no standard treatment option for recurrent OCCC. Herein, we report the case of a 32-year-old female patient with OCCC. The…
[3] score=0.7083 PMID 32104073 [@pubmed:32104073]
    Recurrence Patterns and Survival Outcomes in Chinese Patients with Surgically Treated Recurrent Ovarian Clear Cell Carcinoma: A Single Institutional Analysis of 45 Cases.
    To evaluate the recurrence patterns and survival outcomes of surgically treated relapsed ovarian clear cell carcinoma (OCCC) patients.            We performed a comprehensive retrospective analysis of all the patients who underwent secondary debulking from 2004/10 to 2019/04.            In total, 45…
[4] score=0.6979 PMID 33758607 [@pubmed:33758607]
    Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.
    Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC) and has a high prevalence in Asia without specific molecular subtype classification. Endometriosis is a recognized precancerous lesion that carries 3-fold increased risk of OCCC. Ovarian endometr…
[5] score=0.6896 PMID 37901720 [@pubmed:37901720]
    Case Series and a Literature Review: Two Ovarian Clear Cell Carcinoma Cases with Recurrent Endometriosis.
    Endometriosis-associated ovarian cancer (EAOC) is rare, occurring approximately in 1% of women with ovarian endometriosis. The main histological types are endometrioid adenocarcinoma and clear cell carcinoma (CCC), with the latter being the least common.            In our hospital, we recently summa…</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6529614329338074,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ﬁrst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciﬁcally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6418771147727966,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 14,
    &quot;text&quot;: &quot;ff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.\ngg Data are limited on primary and maintenance therapy for recurrent/\npersistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated\nas indicated with tumor markers and repeat imaging (with modalities\npreviously used) to document response and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\njj Patients who do not respond and progress on two consecutive regimens\nwithout evidence of clinical benefits have diminished likelihood of\nbenefitting from additional therapy (Griffiths RW, et al. Int J Gynecol\nCancer 2011;21:58-65). Decisions to offer clinical trials, supportive care,\nor additional therapy should be made on an individual basis.\nkk Localized radiation therapy (RT) can be considered to palliate\nsymptoms and/or for oligometastatic disease.\nOV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6259449124336243,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000&quot;,
    &quot;page&quot;: 17,
    &quot;text&quot;: &quot;17\nTable 1\nIndications for in vivo ovarian tissue preservation in ovarian\nneoplasms according to the histological type and the stage\nof the disease\nSTAGE\nEPITHELIAL OVARIAN NEOPLASMS\nNON-EPITHELIAL OVARIAN NEOPLASMS\nBOT1\nLGSC\nLGEC\nMCexp\nCCC\nHGSC\nHGEC\nMCinf\nGCT2\nSCC\nGrCT\nSLCT3\nSLCT4\nIA\nIB\nIC1\nIC2\n##\nIC3\n##\nII-IV\n#\n\nfavourable oncologic selection criteria for fertility-sparing management as defined in\nthe text (based on the favourable survival and/or recurrence rates observed in cohorts and/\nor comparative studies (radical versus conservative) of patients treated with such characteris-\ntics).\n\noncologic selection criteria acceptable in selected cases (insufficient or conflicting data\nto evaluate accurately the results of the ovarian preservation in this subgroup of patients).\n\nunfavourable oncologic selection criteria for ovarian preservation (poorest survival\nobserved in patients having an ovarian preservation in these subgroups. It could be related\nto the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6247340440750122,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_nonepithelialovarian_2018__v00000000&quot;,
    &quot;page&quot;: 13,
    &quot;text&quot;: &quot;nately, none of them has been compared with BEP in randomised\ntrials. A phase II Gynecologic Oncology Group (GOG) trial\nreported high activity with an acceptable toxicity proﬁle for a\ncarboplatin–etoposide combination in the adjuvant setting\nof completely resected stages I–III dysgerminomas [40].\nDysgerminomas are very sensitive to RT; however, its use is lim-\nited to selected cases because of the negative impact on fertility.\nIn patients with platinum-sensitive relapse (progression\n&gt; 4–6 weeks after completion of ChT), ifosfamide/platinum (IP)\nwith or without paclitaxel (P) should be considered as second-\nline treatment [IV, C] [41]. Further active ChT regimens include:\nvinblastine/ifosfamide/cisplatin (VeIP) and cisplatin/vinblastine/\nbleomycin (PVB) [IV, C] [42]. Patients resistant to a cisplatin-\nbased combination may receive vincristine/actinomycin D/cyclo-\nphosphamide (VAC) or paclitaxel/gemcitabine or gemcitabine/\noxaliplatin as salvage therapy [IV, C].\nAlthough there is a role for ASCT in relapsed testicular cancer, it\nis not the standard of care for women with relapsed or recurrent\nmalignant ovarian GCTs and its role remains undeﬁned because of&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6238462924957275,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\n• Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n ◊If not previously used (category 1)\n ◊If disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.728381735672506,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;36591227&quot;,
    &quot;title&quot;: &quot;Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Advanced endometrial clear cell carcinoma (CCC) tends to have poor prognosis owing to aggressive clinical behavior and poor response to conventional chemotherapy. Herein, we report a case of platinum-refractory recurrent ECCC successfully treated with the combination of pembrolizumab, localized radiotherapy and a few cycles of chemotherapy with an extremely durable response even after cessation of immunotherapy for 3 years at the time of publication.&quot;,
    &quot;journal&quot;: &quot;Front Immunol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fimmu.2022.1079253&quot;,
    &quot;impact_factor&quot;: 5.9,
    &quot;similarity&quot;: 0.728381735672506
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.7255972016119496,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;35401005&quot;,
    &quot;title&quot;: &quot;Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.&quot;,
    &quot;abstract&quot;: &quot;Ovarian clear cell carcinoma (OCCC) is a highly aggressive malignancy with a poor prognosis, and most patients experience recurrence after primary treatment. Currently, there is no standard treatment option for recurrent OCCC. Herein, we report the case of a 32-year-old female patient with OCCC. The patient received primary cytoreductive surgery with adjuvant chemotherapy and remained disease-free for four months. She then experienced retroperitoneal lymph node recurrence and was treated with liposomal doxorubicin chemotherapy followed by secondary debulking surgery. The patient experienced a second relapse in the lower left lung 11 months later. Genomic profiling of tumor samples revealed a deleterious AT-rich interactive domain 1A (ARID1A) mutation and homologous recombination deficiency. Thus, the triplet combination of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib; the PD-1 inhibitor, pembrolizumab; and the antiangiogenic agent, bevacizumab was administered. The patient achieved partial response, which was sustained for 12 months. Our study provides the first clinical evidence that the combination of olaparib with pembrolizumab and bevacizumab could be an effective treatment for patients with platinum-resistant, recurrent OCCC.&quot;,
    &quot;journal&quot;: &quot;Onco Targets Ther&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/OTT.S362267&quot;,
    &quot;impact_factor&quot;: 2.8,
    &quot;similarity&quot;: 0.7255972016119496
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.7083356140742779,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;32104073&quot;,
    &quot;title&quot;: &quot;Recurrence Patterns and Survival Outcomes in Chinese Patients with Surgically Treated Recurrent Ovarian Clear Cell Carcinoma: A Single Institutional Analysis of 45 Cases.&quot;,
    &quot;abstract&quot;: &quot;To evaluate the recurrence patterns and survival outcomes of surgically treated relapsed ovarian clear cell carcinoma (OCCC) patients.\n          \nWe performed a comprehensive retrospective analysis of all the patients who underwent secondary debulking from 2004/10 to 2019/04.\n          \nIn total, 45 eligible patients were included. 75.6% of the patients had early-stage disease and platinum-sensitive recurrence accounted for 70.5%. The median progression-free survival after primary surgery (PFS 1) was 20 months (range, 2-137). Of all, 64.4% patients had solitary recurrence and 86.7% patients had no residual disease after secondary surgery. Regarding tumor distribution, the most common site was pelvis (47.5%), followed by lymph node metastases (18.0%) and abdominal wall lesions (8.2%). For the entire population, the median disease-free survival after recurrence (PFS 2) and post-relapse survival (PRS) was 15 months (range, 0-96), and 24 months (range, 3-159), respectively. Eight patients (17.8%) had a prolonged PFS2 more than 30 months. Patients with localized relapse had better survival including PFS 2 (P=0.023), PRS (P=0.004), and overall survival (OS) (P=0.029). Patients who achieved complete resection tended to have longer PFS 2 (P=0.017). After multivariate analysis, complete resection at recurrence remained as an independent positive predictor for PFS 2 (P=0.022). The median OS was 50 months and was significantly associated with platinum response (P=0.003) and number of relapsed lesions (P=0.002).\n          \nA high rate of pelvic recurrence was noted in this population. Patients with focal recurrence had a favorable prognosis. Complete resection at secondary debulking proved to be an independent predictor for disease-free survival.&quot;,
    &quot;journal&quot;: &quot;Cancer Manag Res&quot;,
    &quot;pub_date&quot;: &quot;2020-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/CMAR.S242129&quot;,
    &quot;impact_factor&quot;: 2.6,
    &quot;similarity&quot;: 0.7083356140742779
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6978596373994576,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;33758607&quot;,
    &quot;title&quot;: &quot;Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC) and has a high prevalence in Asia without specific molecular subtype classification. Endometriosis is a recognized precancerous lesion that carries 3-fold increased risk of OCCC. Ovarian endometrioid carcinoma, which also originates from endometriosis, shares several features with OCCC, including platinum resistance and younger age at diagnosis. Patients with OCCC have about a 2.5 to 4 times greater risk of having a venous thromboembolism (VTE) compared with other EOC, and OCCC tends to metastasize through lymphatic vesicular and peritoneal spread as opposed to hematogenous metastasis. There is only mild elevation of the conventional biomarker CA125. Staging surgery or optimal cytoreduction combined with chemotherapy is a common therapeutic strategy for OCCC. However, platinum resistance commonly portends a poor prognosis, so novel treatments are urgently needed. Targeted therapy and immunotherapy are currently being studied, including PARP, EZH2, and ATR inhibitors combined with the synthetic lethality of ARID1A-dificiency, and MAPK/PI3K/HER2, VEGF/bFGF/PDGF, HNF1β, and PD-1/PD-L1 inhibitors. Advanced stage, suboptimal cytoreduction, platinum resistance, lymph node metastasis, and VTE are major prognostic predictors for OCCC. We focus on update pathogenesis, diagnostic methods and therapeutic approaches to provide future directions for clinical diagnosis and treatment of OCCC.&quot;,
    &quot;journal&quot;: &quot;J Cancer&quot;,
    &quot;pub_date&quot;: &quot;2021-01-01&quot;,
    &quot;doi&quot;: &quot;10.7150/jca.53395&quot;,
    &quot;impact_factor&quot;: 3.2,
    &quot;similarity&quot;: 0.6978596373994576
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6895975691467441,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;37901720&quot;,
    &quot;title&quot;: &quot;Case Series and a Literature Review: Two Ovarian Clear Cell Carcinoma Cases with Recurrent Endometriosis.&quot;,
    &quot;abstract&quot;: &quot;Endometriosis-associated ovarian cancer (EAOC) is rare, occurring approximately in 1% of women with ovarian endometriosis. The main histological types are endometrioid adenocarcinoma and clear cell carcinoma (CCC), with the latter being the least common.\n          \nIn our hospital, we recently summarized two patients with ovarian clear cell carcinoma with similar characteristics. They all had endometriosis for a long time and had undergone ovarian cyst removal due to a chocolate cyst. Unfortunately, the cyst recurred after surgery, and the histological diagnosis was clear cell carcinoma. In case 1, the expression of P53 was found in the tumor by regular examination, and the stage was IIB. In Case 2, we found it in intraoperative freezing; the stage was IA. Case 1 has been treated with the TP regimen six times, and the survival period has reached one year. Case 2 had a survival period of 6 years after completing six TP regimen treatments. Clinicians should pay attention to patients with a long history of endometriosis and postoperative recurrence of ovarian cysts accompanied by serum CA-125 of more than 200U/mL. Imaging examination has a good prospect in diagnosing malignant transformation of endometriosis, especially PET-CT.\n          \nThis case report highlights the risk factors related to the formation of ovarian clear cell carcinoma and suggests that the follow-up of patients with ovarian endometriosis is essential because of its recurrence characteristics. Radical surgery and postoperative platinum-containing chemotherapy are the primary treatment methods at present.&quot;,
    &quot;journal&quot;: &quot;Int J Womens Health&quot;,
    &quot;pub_date&quot;: &quot;2023-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/IJWH.S418135&quot;,
    &quot;impact_factor&quot;: 2.6,
    &quot;similarity&quot;: 0.6895975691467441
  }
]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- In recurrent epithelial ovarian cancer, selection between PARP inhibitors and anti-VEGF therapy at relapse should consider histologic subtype, BRCA1/2 mutation status, prior PARP or bevacizumab exposure, and cumulative platinum exposure, as these factors influence benefit and toxicity from further platinum and targeted agents [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10].

- Definitions of platinum-sensitive versus platinum-resistant ovarian cancer represent a continuum; NCCN recommends using clinical judgment and flexibility when determining systemic therapy choices and maintenance strategies in recurrent disease, particularly in less common histologies such as low-grade or clear cell tumors where data are limited [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].

- ESGO/ESHRE/ESGE guidance on fertility preservation stratifies the safety of in vivo ovarian tissue preservation by epithelial versus non-epithelial histology and by FIGO stage (IA–IC2), emphasizing that fertility-sparing approaches are more restricted in high-grade or clear cell epithelial cancers compared with borderline or non-epithelial tumors [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000|17].

- For completely resected stage I–III ovarian dysgerminoma, carboplatin–etoposide has shown high activity with acceptable toxicity in phase II data and is considered a reasonable adjuvant alternative to BEP where toxicity concerns or comorbidities make BEP less suitable [@guideline:esmo_cpg_nonepithelialovarian_2018__v00000000|13].

- At first or subsequent recurrence of epithelial ovarian cancer, NCCN recommends considering secondary cytoreductive surgery in appropriate candidates and using platinum-based chemotherapy as preferred for platinum-sensitive relapse (category 1), while also integrating best supportive care discussions according to patient status and preferences [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].

- A case of platinum-refractory metastatic endometrial clear cell carcinoma achieved a durable response to pembrolizumab combined with localized radiotherapy, suggesting that immune checkpoint inhibition plus radiation (potential abscopal effect) may be an option in highly selected, heavily pretreated clear cell endometrial cancers lacking standard effective therapies [@pubmed:36591227].

- A reported ovarian clear cell carcinoma with ARID1A mutation showed a remarkable response to third-line triplet therapy with olaparib, pembrolizumab, and bevacizumab, supporting consideration of PARP inhibitor plus immunotherapy and anti-VEGF combinations in molecularly selected, heavily pretreated clear cell ovarian cancer when standard regimens are exhausted [@pubmed:35401005].

- In a single-institution series of 45 patients undergoing secondary debulking for recurrent ovarian clear cell carcinoma, surgical cytoreduction at relapse was feasible and associated with defined survival outcomes, supporting consideration of secondary debulking in carefully selected OCCC patients with resectable disease [@pubmed:32104073].

- Contemporary reviews highlight that ovarian clear cell carcinoma is biologically distinct, frequently associated with endometriosis, and often exhibits chemoresistance; this underpins the need to prioritize complete initial cytoreduction, consider clinical trials and targeted/immunotherapy strategies, and account for unique molecular features (e.g., ARID1A alterations) in treatment planning [@pubmed:33758607].

- Case series of ovarian clear cell carcinoma arising in the context of endometriosis emphasize that endometriosis-associated ovarian cancer, though rare, warrants vigilant long-term follow-up and timely imaging/surgical evaluation of suspicious endometriotic lesions, given the aggressive behavior of clear cell histology once malignant transformation occurs [@pubmed:37901720].</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Guideline+PubMed RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-19T08:26:17.761260&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-03 08:53:29.260000&quot;,
      &quot;meta_info&quot;: &quot;340123197709263626&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:26:17.761689&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;efe856c0897d&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:26:18.070450&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 92,
      &quot;img_n&quot;: 10,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-04 08:53:29&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:26:26.035914&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:26:26.042939&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=卵巢癌复发; histology=首先考虑为透明细胞癌; components=高级别腺癌\nPATHOLOGY: 部分直乙结肠+左侧腹膜后肿瘤+部分阴道: 肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌；可符合卵巢透明细胞癌累及。\nPLATINUM: status=Resistant; pfi_days=56\nGENETICS: HRD=Unknown; BRCA1=Unknown; BRCA2=Unknown\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=&lt;0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; note=ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PAL…&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:01.058607&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Recurrent platinum-resistant ovarian clear cell carcinoma post debulking and paclitaxel/carboplatin, with liver, pelvic/peritoneal, sacral and right iliac bone metastases; MMR-proficient; ER/PR low positive; performance/organ function constraints not documented; histology: clear cell carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:01.058625&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:01.058627&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:01.058629&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 10
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:12.657342&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:12.657403&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:15.856422&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 553
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:15.856508&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:18.903307&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 554
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:18.903335&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:23.071373&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 566
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:23.071443&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:26.459680&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 401
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:26.459757&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:27:31.648161&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 543
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:31:17.255901&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 2260
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:31:17.258694&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:31:20.673565&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: true
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:31:20.673582&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:31:33.714145&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 1227
    }
  }
]</pre>
  </details>

</body>
</html>
